## **Stelara (Ustekinumab)**



**REFERRAL STATUS:** □ New Referral □ Dose or Frequency Change □ Order Renewal **Infusion Office Preference:** \_\_\_\_\_

PATIENT INFORMATION				
Date:	Patient Name:	DOB:		
□ NKDA Allergie	s:	Weight (lbs / kg): Height:		
Patient Status:   New to Therapy   Continuing Therapy - La		st Treatment Date: Next Due Date:		
PROVIDER INFORMATION				
Office Contact Name:		Office Email:		
Prescribing Providers Name:		Provider NPI:		
Office Address:		City:	Sta	te: Zip:
Office Phone Number:		Office Fax Numb	er:	
DIAGNOSIS AND ICD 10 CODE				
☐ Crohn's Disease		ICD-10 Code:	K50.90	
□ Ulcerative Colit	is	ICD-10 Code:	K51.90	
☐ Other Diagnosis	S:	ICD-10 Code:		
REQUIRED DOCUMENTATION/Testing				
☐ Patient demog	er form by the provider raphics AND insurance info ss notes supporting primary dx	□ Confirmed n	egative TB test	ing
List Tried & Failed Therapies, including duration of treatment: 1) 2)				
MEDICATION ORDERS				
Please check box ☐ if ok to substitute with a Ustekinumab biosimilar per insurance preferred product				
Initial IV dose (choose one):	☐ Stelara 260mg IV x1 for Weight <55kg☐ Stelara 390mg IV x1 for Weight 55-85kg☐ Stelara 520mg IV x1 for Weight >85kg			
Maintenance dosing	<ul> <li>□ Stelara 90mg SQ every 8 weeks (starting 8 weeks after the initial iv dose)</li> <li>□ Stelara 90mg SQ every weeks</li> <li>□ Office will obtain auth for SQ dosing for self administration</li> </ul>			
Provider Name (P	rint) Physician Signat	ture:		Date: